Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Peter A. Kaufman, Hans Wildiers, Gilles Freyer, Margaret Kemeny, Anthony Gonçalves, Guy Jerusalem, Alison Stopeck, Nandagopal Vrindavanam, Florence Dalenc, Nuwan Nanayakkara, Benjamin Wu, Cheryl A. Pickett

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Given the potential interactions between human epidermal growth factor receptor 2 (HER2) signaling and angiogenesis, we investigated the angiopoietin (Ang) 1/Ang2 inhibitor trebananib plus trastuzumab and paclitaxel in HER2-positive breast cancer. Forty women received trebananib (10 or 30 mg/kg) plus trastuzumab and paclitaxel. The combination demonstrated acceptable toxicity and antitumor response in HER2-positive locally recurrent/metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)47-57
Number of pages11
JournalClinical Breast Cancer
Volume19
Issue number1
DOIs
StatePublished - Feb 2019

Keywords

  • AMG 386
  • Angiogenesis
  • Angiopoietin
  • HER2 positive

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer'. Together they form a unique fingerprint.

  • Cite this

    Kaufman, P. A., Wildiers, H., Freyer, G., Kemeny, M., Gonçalves, A., Jerusalem, G., Stopeck, A., Vrindavanam, N., Dalenc, F., Nanayakkara, N., Wu, B., & Pickett, C. A. (2019). Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer, 19(1), 47-57. https://doi.org/10.1016/j.clbc.2018.09.012